All 8 patients in two groups achieved complete response (CR) with minimal residual disease negative; even the patient with central nervous system leukemia (CNSL) relapse who received KIRS2/Dap12-BB CAR-T cells also achieved CR, as confirmed by cerebrospinal fluid. The gene discussed is TYROBP; the disease is central nervous system leukemia.